Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of systemic defects in its Novum IQ Large Volume Pump, which resulted in serious patient risks and a significant drop in stock price following the announcement of a pause in shipments [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of its Novum LVP, which led to malfunctions and patient risks [3]. Group 2: Allegations Against Baxter - Specific allegations include that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP but failed to adequately address these issues [3]. - The lawsuit claims that Baxter's customer alerts were insufficient and that design flaws persisted, leading to serious harm [3]. - Following Baxter's announcement on July 31, 2025, to pause shipments of the Novum LVP, the company's stock price fell by more than 22% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [5]. Group 4: Company Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, including securing the largest securities class action recovery in history at $7.2 billion in the Enron case [6].

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for alleged securities fraud and unlawful business practices [2] - Baxter announced a voluntary and temporary pause in shipments and installations of its Novum LVP medical device, impacting its stock price significantly [2] Company Overview - Baxter International, Inc. is involved in the medical device sector, specifically focusing on intravenous fluid delivery systems [2] - The company has offered an alternative product, the Spectrum infusion pump, to customers affected by the pause in Novum LVP shipments [2] Financial Impact - Following the announcement of the shipment pause, Baxter's stock price dropped by $6.29 per share, representing a 22.4% decline, closing at $21.76 per share on July 31, 2025 [2]

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and systemic defects in its Novum IQ Large Volume Pump, which have resulted in significant patient risks and a notable decline in stock price [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc." and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter and its executives violated the Securities Exchange Act of 1934 by making false statements and failing to disclose critical information regarding the Novum LVP [3]. Group 2: Allegations Against Baxter - The lawsuit claims that the Novum LVP had systemic defects leading to malfunctions such as underinfusion and overinfusion, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures [3]. - On July 31, 2025, Baxter announced a voluntary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in the company's stock price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed systemic defects in its Novum IQ Large Volume Pump, which have resulted in serious patient risks and a significant drop in stock price [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter's Novum IQ Large Volume Pump had systemic defects leading to malfunctions that posed risks of serious injury or death to patients [3]. Group 2: Allegations Against Baxter - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but failed to adequately address these issues [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which contributed to a more than 22% drop in the company's stock price [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed systemic defects in its Novum IQ Large Volume Pump, which have resulted in serious risks to patients and significant stock price decline [3][4]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. - The lawsuit claims that Baxter's Novum IQ LVP suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures, which continued to expose patients to harm [3]. Group 2: Impact on Company Operations - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, unable to provide a timeline for resuming operations [4]. - The company suggested an alternative product, the Spectrum infusion pump, to customers while indicating that its low-end guidance assumes no resumption of Novum LVP shipments before year-end [4]. - Following the announcement, Baxter's stock price dropped by more than 22%, reflecting investor concerns over the ongoing issues with the Novum LVP [4].

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump, which reportedly has systemic defects that pose serious risks to patients [3][4]. Summary by Sections Class Action Lawsuit Details - The lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the class action [1]. Allegations Against Baxter - Baxter allegedly made false or misleading statements and failed to disclose significant issues with the Novum IQ LVP, including systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - The company was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues were deemed inadequate, as design flaws persisted, continuing to harm patients [3]. Impact on Stock Price - Following Baxter's announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, the company's stock price fell by more than 22% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to systemic defects in its Novum IQ Large Volume Pump, which posed serious risks to patients [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter made false or misleading statements regarding the Novum IQ Large Volume Pump, which suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - The company announced on July 31, 2025, a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in its stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [6].